Finding the proverbial needle: Non-targeted screening of synthetic opioids in equine plasma
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Finding the proverbial needle : Non-targeted screening of synthetic opioids in equine plasma. / Klingberg, Joshua; Cawley, Adam; Shimmon, Roznald; Fouracre, Chris; Pasin, Daniel; Fu, Shanlin.
In: Drug Testing and Analysis, Vol. 13, No. 5, 05.2021, p. 977-989.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Finding the proverbial needle
T2 - Non-targeted screening of synthetic opioids in equine plasma
AU - Klingberg, Joshua
AU - Cawley, Adam
AU - Shimmon, Roznald
AU - Fouracre, Chris
AU - Pasin, Daniel
AU - Fu, Shanlin
N1 - © 2020 John Wiley & Sons, Ltd.
PY - 2021/5
Y1 - 2021/5
N2 - Synthetic opioids are a class of compounds that are of particular concern due to their high potency and potential health impacts. With the relentless emergence of new synthetic opioid derivatives, non-targeted screening strategies are required that do not rely on the use of library spectra or reference materials. In this study, product ion searching, and Kendrick mass defect analysis were investigated for non-targeted screening of synthetic opioids. The estimated screening cut-offs for these techniques ranged between 0.05 and 0.1 ng/mL. These techniques were designed to not be reliant on a particular vendor's software, meaning that they can be applied to existing drug screening protocols, without requiring the development and validation of new analytical procedures. The efficacy of the developed techniques was tested through blind trials, with spiked samples inserted amongst authentic plasma samples, which demonstrated the usefulness of these methods for high-throughput screening. The use of a non-targeted screening workflow that contains complementary techniques can increase the likelihood of detecting compounds of interest within a sample, as well as the confidence in detections that are made.
AB - Synthetic opioids are a class of compounds that are of particular concern due to their high potency and potential health impacts. With the relentless emergence of new synthetic opioid derivatives, non-targeted screening strategies are required that do not rely on the use of library spectra or reference materials. In this study, product ion searching, and Kendrick mass defect analysis were investigated for non-targeted screening of synthetic opioids. The estimated screening cut-offs for these techniques ranged between 0.05 and 0.1 ng/mL. These techniques were designed to not be reliant on a particular vendor's software, meaning that they can be applied to existing drug screening protocols, without requiring the development and validation of new analytical procedures. The efficacy of the developed techniques was tested through blind trials, with spiked samples inserted amongst authentic plasma samples, which demonstrated the usefulness of these methods for high-throughput screening. The use of a non-targeted screening workflow that contains complementary techniques can increase the likelihood of detecting compounds of interest within a sample, as well as the confidence in detections that are made.
U2 - 10.1002/dta.2893
DO - 10.1002/dta.2893
M3 - Journal article
C2 - 32627304
VL - 13
SP - 977
EP - 989
JO - Drug Testing and Analysis
JF - Drug Testing and Analysis
SN - 1942-7603
IS - 5
ER -
ID: 244824024